Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 396-402

  Wang, Biyun ^a   Lu, Jiade ^b   Ma, Xuejun ^a   Guo, Ye ^a   Lu, Hongfen ^a   Hong, Xiaonan ^a   Li, Jin ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; LOMUSTINE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; EARLY CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NATURAL KILLER T CELL; NOSE CAVITY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; FOLLOW UP; MIDDLE AGED; NATURAL KILLER CELL; NOSE TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NOSE NEOPLASMS; PREDNISONE; PROGNOSIS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; VINCRISTINE;

EID: 34247899237     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601059795     Document Type: Article

References (30)

1. Ko, Y. H., Kim, C. W., Park, C. S., Jang, H. K., Lee, S. S. and Kim, S. H. (1998) REAL classification of malignant lymphomas in the Republic of Korea: Incidence of recently recognized entities and changes in clinicopathologic features. Cancer, 83, pp. 806-812.
2. Proulx, G. M., Caudra-Garcia, I., Ferry, J., Harris, N., Greco, W. R. and Kaya, U. (2003) Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol, 26, pp. 6-11.
3. Hirakawa, S., Kuyama, M., Takahashi, S., Yamasaki, O., Kanzaki, H. and Teshima, T. (1999) Nasal and nasal-type natural killer/T-cell lymphoma. J Am Acad Dermatol, 40, pp. 268-272.
4. Liang, R., Todd, D., Chan, T. K., Chiu, E., Lie, A. and Kwong, Y. L. (1995) Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol, 13, pp. 666-670.
5. Au, W. Y., Ma, S. Y., Chim, C. S., Choy, C., Loong, F. and Lie, A. K. (2005) Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol, 16, pp. 206-214.
6. Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M. and Grogan, T. M. (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med, 339, pp. 21-26.
7. Li, Y. X., Yao, B., Jin, J., Wang, W. H., Liu, Y. P. and Song, Y. W. (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol, 24, pp. 181-189.
8. Lee, J., Park, Y. H., Kim, W. S., Lee, S. S., Ryoo, B. Y. and Yang, S. H. (2005) Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer, 41, pp. 1403-1408.
9. Jaffe, E. S., Harris, N. L., Stein, H. and Vardiman, J. W. (2001) Pathology and genetics of tumors of hematopoietic and lymphoid tissues. World Health Organization classification of tumors, IARC Press, Lyon, France
10. Chan, J. K., Ng, C. S., Lau, W. H. and Lo, S. T. (1987) Most nasal/ nasopharyngeal lymphomas are peripheral T-Cell neoplasms. Am J Surg Pathol, 11, pp. 418-429.
11. Ng, C. S., Chan, J. K. and Lo, S. T. (1987) Expression of natural killer cell markers in non-Hodgkin's lymphomas. Hum Pathol, 18, pp. 1257-1262.
12. Chan, J. K., Tsang, W. Y. and Pau, M. Y. (1995) Discordant CD3 expression in lymphomas as studied on frozen and paraffin sections. Hum Pathol, 26, pp. 1139-1143.
13. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
14. Cox, D. R. (1982) Regression models and life-tables. J Stat Soc, 34, pp. 187-220.
15. Cox, J. D., Stetz, J. and Pajak, T. F. (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 31, pp. 1341-1346.
16. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. and Cleary, M. L. (1994) A revised European-American Classification of lymphoid neoplasm: A proposal from the International Lymphomas Study Group. Blood, 84, pp. 1361-1392.
17. Kim, W. S., Song, S. Y., Ahn, Y. C., Ko, Y. H., Baek, C. H. and Kim, D. Y. (2001) CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol, 12, pp. 349-352.
18. Kim, T. M., Park, Y. H., Lee, S. Y., Kim, J. H., Kim, D. W. and Im, S. A. (2005) Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood, 106, pp. 3785-3790.
19. Lee, J., Sun, C., Park, Y. H., Ko, Y. H., Bang, S. M. and Lee, J. H. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol, 24, pp. 612-618.
20. Cheung, M. M., Chan, J. K., Lau, W. H., Ngan, R. K. and Foo, W. W. (2002) Early stage nasal NK/T-cell lymphoma: Clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys, 54, pp. 182-190.
21. Tham, I. W., Lee, K. M., Yap, S. P. and Loong, S. L. (2005) Outcome of patients with nasal natural killer (NK)/T-cell lymphoma treated with radiotherapy, with or without chemotherapy. Head and Neck, 28, pp. 126-134.
22. Palmieri, G., Lauria, R., Caponigro, F., Pagliarulo, C., Montesarchio, V. and Nuzzo, F. (1990) Salvage chemotherapy for non Hodgkin's lymphoma of unfavorable histology with a combination of CCNU and vinblastine. Hematol Oncol, 8, pp. 179-183.
23. Dorigo, A., Mansberg, R. and Kwan, Y. L. (1993) Lomustine, etoposide, methotrexate and prednisone (LEMP) therapy for relapsed and refractory non-Hodgkin's lymphoma. Eur J Haematol, 50, pp. 37-40.
24. Shamash, J., Walewski, J., Apostolidis, J., Wilson, A. M., Foran, J. M. and Gupta, R. K. (2000) Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol, 11, pp. 857-860.
25. Musolino, A., Perrone, M. A., Michiara, M., Delnevo, D., Franciosi, V. and Blasio, B Di (2005) Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma. Cancer, 103, pp. 2109-2117.
26. Kim, G. E., Cho, J. H., Yang, W. I., Chung, E. J., Suh, C. O. and Park, K. R. (2000) Angiocentric lymphoma of the head and neck: Pattern of systemic failure after radiation treatment. J Clin Oncol, 18, pp. 54-63.
27. Shikama, N., Izuno, I., Oguchi, M., Gomi, K., Sone, S. and Takei, K. (1997) Clinical stage IE primary lymphoma of the nasal cavity: Radiation therapy and chemotherapy. Radiology, 204, pp. 467-470.
28. Li, C. C., Tien, H. F., Tang, J. L., Yao, M., Chen, Y. C. and Su, I. J. (2004) Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer, 100, pp. 366-375.
29. Yong, W., Zheng, W., Zhang, Y., Zhu, J., Wei, Y. and Zhu, D. (2003) L-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Intl J Hematol, 78, pp. 163-167.
30. Liang, R., Chen, F., Lee, C. K., Kwong, Y. L., Chim, C. S. and Yau, C. C. (1997) Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant, 19, pp. 91-93.